Sanofi SA (NASDAQ:SNY) released results from the IRAKLIA phase 3 study evaluating the non-inferiority of Sarclisa (isatuximab ...

Also Read: Sanofi’s 340B Credit Proposal Draws Federal Warning For Statutory Violation Key secondary endpoints were also achieved, including very good partial response, the incidence rate of ...

Sanofi (SYN) 43rd Annual J.P. Morgan Healthcare January 14, 2025 12:45 PM ETCompany ParticipantsPaul Hudson - Chief Executive OfficerFrancois-Xavier Roger ...

The 340B requirement has long been a bone of contention ... Last year, for example, a federal appeals court sided with Sanofi, AstraZeneca, and Novo Nordisk in a dispute claiming that recipients ...

To date, we have seen four drug companies (Johnson & Johnson, Eli Lilly, Bristol Meyers Squibb, and Sanofi) attempt to establish a 340B rebate model, and we anticipate more drug companies will pursue ...

Novartis sues HHS over rejection of a proposed 340B rebate model, arguing it enhances transparency and compliance while ...

The 340B program, once a lifeline for underserved communities, has become a case study in crony capitalism. Designed to help hospitals serving low-income patients by offering discounted ...

The 340B Drug Pricing Program is a federal lifeline for vulnerable and underserved communities across the U.S., and its importance in Orlando is profound. Created to allow health-care safety-net ...

Sanofi's participation at the JP Morgan 43rd Annual Healthcare Conference on 14 January 2025 was marked by a comprehensive overview of the company's position in 2024 and its strategic vision for t ...

That channel is the 340B Drug Pricing Program, a non-taxpayer-funded, federal program that allows eligible hospitals and clinics to purchase drugs at significantly reduced prices. While the criterion ...